Developer docs
API playgroundTry for free, no card

Search company profiles

Initiator Pharma

Full company profile

uuid0003v6u

Namestring
Initiator Pharma
Legal namestring
Initiator Pharma A/S
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Initiator Pharma A/S is a Danish clinical-stage biotechnology company founded in 2016 and headquartered in Copenhagen, focused on developing small-molecule drugs for unmet medical needs in the central and peripheral nervous system. The portfolio is built around a single proprietary asset, pudafensine (IP2015), an orally administered monoamine reuptake inhibitor that preferentially blocks synaptic reuptake of dopamine followed by serotonin. The lead clinical program, IPVU2025, is a Phase IIa proof-of-concept study in vulvodynia that received UK MHRA approval in November 2025 and began patient enrollment in December 2025; a previously completed Phase IIb study in erectile dysfunction reported positive, statistically significant, dose-dependent efficacy. A preclinical program, IPFSD2023, explores pudafensine in female sexual dysfunction animal models, and the company in April 2026 discontinued the IP2018 program to concentrate resources on pudafensine.

The company is listed on Nasdaq First North Growth Market in Stockholm (ticker: INIT) with Redeye Sweden AB acting as Certified Adviser, and was originally spun off from Saniona AB. Operating geographies include Denmark, the United Kingdom, and the United States (for conference and partnering activity). As a pre-revenue biotech, Initiator Pharma reported FY 2025 net revenue of TDKK 0; capital sources to date include a 2022 SEK 19.999995 million funding round from Adrigo Asset Management AB and Linc AB, a June 2025 rights issue of approximately SEK 48.3 million, and a May 2025 GBP 2.5 million convertible credit facility with MAC Clinical Research covering Phase IIa trial costs. The company is led by co-founder and CEO Claus Elsborg Olesen, alongside co-founders Dan Peters and Ulf Simonsen, with a headcount of 1-10 employees.

The business model is a classic clinical-stage biotech commercialization pathway: develop the asset through clinical proof-of-concept, strengthen the patent estate (European patent EP4551221B1 granted February 2026 covering pudafensine in FSD, with multi-jurisdiction pending applications), and pursue licensing or partnership-driven commercialization at a later stage. Target therapeutic markets are large and underserved, including approximately 27 million women in the US and Europe affected by vulvodynia (no FDA-approved treatment) and 322 million men affected by erectile dysfunction globally by 2025, of whom 40% do not respond to existing drug therapy.

Short descriptiontext

Initiator Pharma A/S is a Danish clinical-stage biotech developing pudafensine, an oral monoamine reuptake inhibitor, for vulvodynia, erectile dysfunction, and female sexual dysfunction, with a Phase IIa vulvodynia study enrolling and revenue generation expected only post-regulatory approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical stage biotechnology, monoamine reuptake inhibitors, neuropathic pain therapeutics, female sexual dysfunction drugs, vulvodynia treatment development
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Central Nervous System Therapeutics (Biopharmaceutical Drug Development)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product development and commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotech company developing innovative drugs. Revenue expected from future product commercialization upon regulatory approval.

initiatorpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Initiator Pharma is a clinical-stage biotech company developing pudafensine (IP2015), an orally administered monoamine reuptake inhibitor for the treatment of vulvodynia, erectile dysfunction, and female sexual dysfunction. The lead program, IPVU2025, is a Phase IIa clinical proof-of-concept study in vulvodynia that initiated patient enrollment in December 2025. The company has no commercialized products and is pre-revenue, expecting future revenue from out-licensing or commercialization upon regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Pudafensine demonstrated statistically significant effect on allodynia (p=0.049) in Phase I pain study
+3 more records
Product overview1 text field

Initiator Pharma A/S is a Danish clinical-stage biotech company developing innovative drugs targeting unmet medical needs within the central and peripheral nervous system. The company's drug development portfolio centers on pudafensine (IP2015), a monoamine reuptake inhibitor with dual mechanism of action for both pain regulation and sexual function, which is currently the lead clinical asset. The pipeline includes pudafensine in Phase IIa for vulvodynia (IPVU2025 program) and previously completed Phase IIb for erectile dysfunction, along with IPFSD2023 in preclinical development for Female Sexual Dysfunction. Following a strategic decision in April 2026, the company discontinued IP2018 to fully concentrate resources on pudafensine. The company is listed on Nasdaq First North Growth Market (ticker: INIT) with Redeye Sweden AB as Certified Adviser.

Product and service4 records
1IPED2015 – Erectile Dysfunction Clinical Program
CategoryClinical-stage pharmaceutical / Erectile Dysfunction Therapeutics
Description

Clinical development program for pudafensine (IP2015) targeting erectile dysfunction, with completed Phase IIb trials showing positive, statistically significant efficacy in men with ED. Targets the ~40% of ED patients who do not respond to current drug therapy.

2IPVU2025 – Neuropathic Pain/Vulvodynia Clinical Program
CategoryClinical-stage pharmaceutical / Neuropathic Pain Therapeutics
Description

Phase IIa clinical proof-of-concept study evaluating pudafensine in 24 women with vulvodynia, a rare disease indication of severe neuropathic pain with no approved treatments. Based on pudafensine API proven safe and tolerable in prior clinical trials. Phase I study showed statistically significant effect on allodynia (p=0.049). Targets the ~10% of women worldwide affected by vulvodynia, including 27 million in the US and Europe.

3IPFSD2023 – Female Sexual Dysfunction Preclinical Program
4Pudafensine (IP2015) Drug Candidate
CategoryPharmaceutical API / Monoamine Reuptake Inhibitor
Description

Pudafensine is the company's lead orally administered monoamine reuptake inhibitor drug candidate with a dual mechanism of action targeting both central pain regulation and sexual function. It preferentially inhibits synaptic reuptake of dopamine followed by serotonin, increasing dopamine levels in the synapse. The active pharmaceutical ingredient underlying all of Initiator Pharma's clinical and preclinical programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MAC Clinical Research is the UK's largest independent clinical development organization. In May 2025, Initiator Pharma entered a convertible credit agreement with MAC under which MAC will take on the cost, up to GBP 2.5 million, for conducting the Phase 2a study evaluating pudafensine in patients with vulvodynia. The study is being conducted at MAC's Dedicated Research Sites in the UK.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS biotech developing small-molecule therapies targeting monoamine neurotransmitter systems. Comparable in clinical-stage profile, monoamine-based mechanism, and CNS therapeutic focus to Initiator Pharma's pudafensine program.

TypeDirect peer
Description

Initiator Pharma was spun off from Saniona in 2016, and Saniona remains its parent/strategic operating shareholder. Saniona is a clinical-stage biotech focused on rare CNS diseases with monoamine-modulating assets, sharing therapeutic area, scientific approach, and Nordic capital-markets profile.

TypeDirect peer
Description

Clinical-stage women's health biotech developing novel therapies for conditions including female sexual dysfunction and vulvar/vaginal disorders. Highly comparable to Initiator Pharma's pudafensine program in vulvodynia and FSD, with similar pre-revenue clinical-stage model and licensing-oriented business strategy.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company applying AI to develop CNS therapies, including agitation and rare neurological conditions. Comparable as a clinical-stage CNS biotech with a lean operating model and small employee footprint.

TypeEmerging player
Description

Clinical-stage biotech focused on genetically defined diseases with small-molecule therapies. Comparable in clinical-stage profile, small-cap public-company structure on Nasdaq, and single-platform-drug-development orientation.

TypeBroad incumbent
Description

Established CNS specialty pharmaceutical company with marketed CNS assets. Relevant as a broader incumbent demonstrating the commercial path for CNS-modulating therapies, though operating at much larger scale and with broader portfolio than Initiator Pharma.

TypeDirect peer
Description

Specialty women's health pharmaceutical company with marketed and pipeline products in female sexual dysfunction and reproductive health. Comparable therapeutic-area focus on women's health conditions overlapping with Initiator Pharma's FSD/vulvodynia programs.

TypeEmerging player
Description

Specialty pharmaceutical company focused on responsible pain management and neuroscience products. Comparable in CNS/neuropathic-pain therapeutic focus and clinical/commercial development model for small patient populations.

TypeBroad incumbent
Description

Global women's health-focused pharmaceutical company with established commercial infrastructure in conditions including sexual health. Comparable in women's health commercial orientation but operates as a broad incumbent with diversified marketed portfolio versus Initiator Pharma's single-asset pre-revenue model.

TypeBroad incumbent
Description

Global specialty pharmaceutical company with established urology/women's health franchises. Comparable end-therapeutic-area overlap (sexual dysfunction, neuropathic pain) but operates as a broad incumbent with diversified portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Initiator Pharma

Central Nervous System Therapeutics (Biopharmaceutical Drug Development)initiatorpharma.com

Initiator Pharma A/S is a Danish clinical-stage biotech developing pudafensine, an oral monoamine reuptake inhibitor, for vulvodynia, erectile dysfunction, and female sexual dysfunction, with a Phase IIa vulvodynia study enrolling and revenue generation expected only post-regulatory approval.

What Initiator Pharma does

Initiator Pharma A/S is a Danish clinical-stage biotechnology company founded in 2016 and headquartered in Copenhagen, focused on developing small-molecule drugs for unmet medical needs in the central and peripheral nervous system. The portfolio is built around a single proprietary asset, pudafensine (IP2015), an orally administered monoamine reuptake inhibitor that preferentially blocks synaptic reuptake of dopamine followed by serotonin. The lead clinical program, IPVU2025, is a Phase IIa proof-of-concept study in vulvodynia that received UK MHRA approval in November 2025 and began patient enrollment in December 2025; a previously completed Phase IIb study in erectile dysfunction reported positive, statistically significant, dose-dependent efficacy. A preclinical program, IPFSD2023, explores pudafensine in female sexual dysfunction animal models, and the company in April 2026 discontinued the IP2018 program to concentrate resources on pudafensine.

The company is listed on Nasdaq First North Growth Market in Stockholm (ticker: INIT) with Redeye Sweden AB acting as Certified Adviser, and was originally spun off from Saniona AB. Operating geographies include Denmark, the United Kingdom, and the United States (for conference and partnering activity). As a pre-revenue biotech, Initiator Pharma reported FY 2025 net revenue of TDKK 0; capital sources to date include a 2022 SEK 19.999995 million funding round from Adrigo Asset Management AB and Linc AB, a June 2025 rights issue of approximately SEK 48.3 million, and a May 2025 GBP 2.5 million convertible credit facility with MAC Clinical Research covering Phase IIa trial costs. The company is led by co-founder and CEO Claus Elsborg Olesen, alongside co-founders Dan Peters and Ulf Simonsen, with a headcount of 1-10 employees.

The business model is a classic clinical-stage biotech commercialization pathway: develop the asset through clinical proof-of-concept, strengthen the patent estate (European patent EP4551221B1 granted February 2026 covering pudafensine in FSD, with multi-jurisdiction pending applications), and pursue licensing or partnership-driven commercialization at a later stage. Target therapeutic markets are large and underserved, including approximately 27 million women in the US and Europe affected by vulvodynia (no FDA-approved treatment) and 322 million men affected by erectile dysfunction globally by 2025, of whom 40% do not respond to existing drug therapy.

Initiator Pharma firmographics

Firmographics
Name
Initiator Pharma
Legal name
Initiator Pharma A/S
Website
https://initiatorpharma.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Initiator Pharma A/S is a Danish clinical-stage biotech developing pudafensine, an oral monoamine reuptake inhibitor, for vulvodynia, erectile dysfunction, and female sexual dysfunction, with a Phase IIa vulvodynia study enrolling and revenue generation expected only post-regulatory approval.
Ownership category
akta.pro rank

Initiator Pharma industry classification

Industry
Product category
Central Nervous System Therapeutics (Biopharmaceutical Drug Development)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals

Keywords

  • Clinical stage biotechnology
  • Monoamine reuptake inhibitors
  • Neuropathic pain therapeutics
  • Female sexual dysfunction drugs
  • Vulvodynia treatment development

Where Initiator Pharma is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Initiator Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical product development and commercialization: Pre-revenue clinical stage biotech company developing innovative drugs. Revenue expected from future product commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Initiator Pharma product offering

Product offering

Core offering

Initiator Pharma is a clinical-stage biotech company developing pudafensine (IP2015), an orally administered monoamine reuptake inhibitor for the treatment of vulvodynia, erectile dysfunction, and female sexual dysfunction. The lead program, IPVU2025, is a Phase IIa clinical proof-of-concept study in vulvodynia that initiated patient enrollment in December 2025. The company has no commercialized products and is pre-revenue, expecting future revenue from out-licensing or commercialization upon regulatory approval.

Product overview

Initiator Pharma A/S is a Danish clinical-stage biotech company developing innovative drugs targeting unmet medical needs within the central and peripheral nervous system. The company's drug development portfolio centers on pudafensine (IP2015), a monoamine reuptake inhibitor with dual mechanism of action for both pain regulation and sexual function, which is currently the lead clinical asset. The pipeline includes pudafensine in Phase IIa for vulvodynia (IPVU2025 program) and previously completed Phase IIb for erectile dysfunction, along with IPFSD2023 in preclinical development for Female Sexual Dysfunction. Following a strategic decision in April 2026, the company discontinued IP2018 to fully concentrate resources on pudafensine. The company is listed on Nasdaq First North Growth Market (ticker: INIT) with Redeye Sweden AB as Certified Adviser.

Differentiator

Problem solved

Functional benefit

Products and services

  • IPED2015 – Erectile Dysfunction Clinical Program Clinical development program for pudafensine (IP2015) targeting erectile dysfunction, with completed Phase IIb trials showing positive, statistically significant efficacy in men with ED. Targets the ~40% of ED patients who do not respond to current drug therapy.
  • IPVU2025 – Neuropathic Pain/Vulvodynia Clinical Program Phase IIa clinical proof-of-concept study evaluating pudafensine in 24 women with vulvodynia, a rare disease indication of severe neuropathic pain with no approved treatments. Based on pudafensine API proven safe and tolerable in prior clinical trials. Phase I study showed statistically significant effect on allodynia (p=0.049). Targets the ~10% of women worldwide affected by vulvodynia, including 27 million in the US and Europe.
  • IPFSD2023 – Female Sexual Dysfunction Preclinical Program
  • Pudafensine (IP2015) Drug Candidate Pudafensine is the company's lead orally administered monoamine reuptake inhibitor drug candidate with a dual mechanism of action targeting both central pain regulation and sexual function. It preferentially inhibits synaptic reuptake of dopamine followed by serotonin, increasing dopamine levels in the synapse. The active pharmaceutical ingredient underlying all of Initiator Pharma's clinical and preclinical programs.

Quantifiable outcome

  • Pudafensine demonstrated statistically significant effect on allodynia (p=0.049) in Phase I pain study
  • +3 more outcomes

Companies that use Initiator Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Initiator Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Initiator Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MAC Clinical ResearchcoreStrategic or Co-development PartnerMAC Clinical Research is the UK's largest independent clinical development organization. In May 2025, Initiator Pharma entered a convertible credit agreement with MAC under which MAC will take on the cost, up to GBP 2.5 million, for conducting the Phase 2a study evaluating pudafensine in patients with vulvodynia. The study is being conducted at MAC's Dedicated Research Sites in the UK.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Initiator Pharma competitors and assessment

Company assessment

Direct peers

  • Minerva Neurosciences: Clinical-stage CNS biotech developing small-molecule therapies targeting monoamine neurotransmitter systems. Comparable in clinical-stage profile, monoamine-based mechanism, and CNS therapeutic focus to Initiator Pharma's pudafensine program.
  • Saniona AB: Initiator Pharma was spun off from Saniona in 2016, and Saniona remains its parent/strategic operating shareholder. Saniona is a clinical-stage biotech focused on rare CNS diseases with monoamine-modulating assets, sharing therapeutic area, scientific approach, and Nordic capital-markets profile.
  • Daré Bioscience: Clinical-stage women's health biotech developing novel therapies for conditions including female sexual dysfunction and vulvar/vaginal disorders. Highly comparable to Initiator Pharma's pudafensine program in vulvodynia and FSD, with similar pre-revenue clinical-stage model and licensing-oriented business strategy.
  • TherapeuticsMD: Specialty women's health pharmaceutical company with marketed and pipeline products in female sexual dysfunction and reproductive health. Comparable therapeutic-area focus on women's health conditions overlapping with Initiator Pharma's FSD/vulvodynia programs.

Emerging players

  • BioXcel Therapeutics: Clinical-stage biopharmaceutical company applying AI to develop CNS therapies, including agitation and rare neurological conditions. Comparable as a clinical-stage CNS biotech with a lean operating model and small employee footprint.
  • Cogent Biosciences: Clinical-stage biotech focused on genetically defined diseases with small-molecule therapies. Comparable in clinical-stage profile, small-cap public-company structure on Nasdaq, and single-platform-drug-development orientation.
  • Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management and neuroscience products. Comparable in CNS/neuropathic-pain therapeutic focus and clinical/commercial development model for small patient populations.

Broad incumbents

  • Acadia Pharmaceuticals: Established CNS specialty pharmaceutical company with marketed CNS assets. Relevant as a broader incumbent demonstrating the commercial path for CNS-modulating therapies, though operating at much larger scale and with broader portfolio than Initiator Pharma.
  • Organon & Co. Global women's health-focused pharmaceutical company with established commercial infrastructure in conditions including sexual health. Comparable in women's health commercial orientation but operates as a broad incumbent with diversified marketed portfolio versus Initiator Pharma's single-asset pre-revenue model.
  • Ipsen: Global specialty pharmaceutical company with established urology/women's health franchises. Comparable end-therapeutic-area overlap (sexual dysfunction, neuropathic pain) but operates as a broad incumbent with diversified portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Initiator Pharma social profiles

Digital presence

Initiator Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Initiator Pharma leadership team

Management profile

Number of profiles

Profiles10 records

Initiator Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Initiator Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Initiator Pharma

What does Initiator Pharma do?

Initiator Pharma is a clinical-stage biotech company developing pudafensine (IP2015), an orally administered monoamine reuptake inhibitor for the treatment of vulvodynia, erectile dysfunction, and female sexual dysfunction. The lead program, IPVU2025, is a Phase IIa clinical proof-of-concept study in vulvodynia that initiated patient enrollment in December 2025. The company has no commercialized products and is pre-revenue, expecting future revenue from out-licensing or commercialization upon regulatory approval.

Is Initiator Pharma a public or private company?

Initiator Pharma is a public company. It is classified as public and is currently operating.

When was Initiator Pharma founded?

Initiator Pharma was founded in 2016. It employs 1 to 10 people.

Where is Initiator Pharma based?

Initiator Pharma is headquartered in Copenhagen, Denmark, in the Europe region.

How does Initiator Pharma make money?

One revenue line is on record: pharmaceutical product development and commercialization.

Who are Initiator Pharma's main competitors?

Direct peers on record are Minerva Neurosciences, Saniona AB, Daré Bioscience and TherapeuticsMD. Emerging players are BioXcel Therapeutics, Cogent Biosciences and Collegium Pharmaceutical. Broad incumbents are Acadia Pharmaceuticals, Organon & Co. and Ipsen.

Does Initiator Pharma have an API?

No public API is recorded for Initiator Pharma.

What industry is Initiator Pharma in?

Initiator Pharma's product category is Central Nervous System Therapeutics (Biopharmaceutical Drug Development). Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewINITIATOR PHARMA: Q3 2026 REPORTInitiator Pharma reported Q3 2026 net revenue of zero and an operating loss of DKK 8,508, with cash at DKK 14,172. The company also announced a directed share issue raising DKK 8.2 million to fund operations into 2028.InitiatorpharmaThe Board of Directors proposes a directed share issue and fully guaranteed rights issue of a total of approximately SEK 61 million to finance its clinical programs into the beginning of 2024 – InitiaInitiator Pharma A/S announced that its Board of Directors has proposed a capital raise of approximately SEK 61 million through a directed share issue and a fully guaranteed rights issue to fund clinical programs into early 2024. The financing is led by anchor investors Linc AB and Adrigo Asset Management AB, who are participating in the directed portion and providing guarantees for the subsequent rights issue at a subscription price of SEK 7.50 per share.MarketScreenerInitiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc ABInitiator Pharma A/S announced an expectation to receive approximately 20 million SEK in funding from Adrigo Asset Management AB and Linc AB. This financial injection supports the company's operations, with Linc AB identified as an active investor in the Nordic Life Science sector.news.cision.comInitiator Pharma: Financial calendar for 2021Initiator Pharma announced its 2021 financial reporting schedule, with the year-end 2020 report due 19 February 2021 and the annual general meeting on 28 May 2021. The company also plans interim reports for Q1, H1, Q3, and the year-end 2021 report.news.cision.comBoard members and management in Initiator Pharma exercise warrantsInitiator Pharma's board and management exercised 324,114 warrants on 23 December 2020, raising about SEK 1.3 million. The exercise increased issued shares by 324,114 and share capital by 34,031.97 DKK, with proceeds of SEK 1,280,250.30.news.cision.comInitiator Pharma strengthens its management team and initiates its Scientific Clinical Advisory BoardInitiator Pharma appointed Dr. Allan Wehnert as SVP of Clinical and R&D Strategy and formed a Scientific and Clinical Advisory Board. The move follows progress in clinical development of lead assets IPED2015 and IP2018, with a financing agreement worth up to 23 MSEK for Phase 2 development.news.cision.comErik Penser Bank publishes analysis of Initiator PharmaErik Penser Bank published an analysis of Initiator Pharma, valuing the clinical-stage biotech at SEK 11-12 based on its two clinical projects. The company's warrants for series TO 2 are exercisable until December 15, 2020.news.cision.comInitiator Pharma – Screening ongoing and first dosing expected soon in Phase 2a trial with IP2018Initiator Pharma announced that patient screening for its Phase 2a trial with IP2018 is ongoing, with first dosing expected shortly. The company clarified that the first patient has not yet been dosed, correcting earlier information. The trial targets psychogenic erectile dysfunction.news.cision.comInitiator Pharma secures funding for IPED2015 clinical Phase 2b study - signs financing agreement with MAC Clinical Research worth up to 23 MSEKInitiator Pharma signed a convertible credit agreement with MAC Clinical Research worth up to 23 MSEK to fund a Phase 2b study of IPED2015 for erectile dysfunction. The study targets PDE5i nonresponders and is planned for H1 2021, with MAC converting debt into shares at 7.5 SEK per share.news.cision.comThe exercise period for Initiator Pharma’s warrants of series TO 2 begins todayInitiator Pharma's warrant exercise period for series TO 2 begins today, 24 November 2020, and ends 15 December 2020. Each warrant allows subscription for one share at SEK 4.90, with full exercise expected to bring SEK 16.4 million before issue costs. Proceeds will finance the clinical phase IIa study for drug candidate IP2018.